San Francisco, CA, October 19, 2022 – Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following categories:
- Tempo-iBMEC™ – Human iPSC-derived Brain Microvascular Endothelial Cells
- Tempo-iPeri™ – Human iPSC-derived Pericytes